Revenue of breast and prostate cancer diagnostics in Europe totaled US$ 3,949.1 million in 2022 and is expected to reach US$ 4,041.5 million by 2023. Over the assessment period, demand for breast and prostate cancer diagnostics across Europe is set to rise at 2.2% CAGR. By 2033, the total revenue in Europe is expected to reach US$ 5,030.1 million.
Revenue in Europe to Expand Around 1.3X through 2033
Breast and prostate cancer diagnostics revenue in Europe is expected to expand by about 1.3X by 2033. This is attributable to the rising prevalence of breast and prostate cancer, the growing needs for early cancer detection, favorable government support, and advancements in cancer diagnostics technology.
Europe is witnessing a dramatic rise in the cases of breast and prostate cancer. This is creating a surging demand for cancer diagnostic testing in countries across Europe, thereby fostering growth.
Government initiatives and screening programs are anticipated to play key roles in boosting revenue across Europe. Several countries in Europe are launching breast screening programs, which are expected to drive demand in the region.
For instance, the new European Cancer Imaging Initiative was launched in December 2022. Such initiatives will present lucrative opportunities for breast and prostate cancer diagnostics companies.
Other trends in breast and prostate cancer diagnosis space in Europe
Biopsy and Liquid Biopsy Segments to Collectively Hold 43% Share
As per the latest Europe breast and prostate cancer diagnostics industry analysis, the biopsy and liquid biopsies segment is expected to hold around 43% share through 2033 collectively. This is due to the rising patient preference for biopsies and liquid biopsies due to their high effectiveness and reliable nature.
Biopsies and liquid biopsies are becoming suitable tools for diagnosing breast and prostate cancer. They are the ideal means to diagnose these cancer types definitively. As a result, medical professionals often recommend these cancer diagnostic tests to patients for early cancer detection.
Advancements in biopsy procedures, such as MRI-targeted biopsies, 3D optical biopsies, and ultrasound-guided biopsies, are anticipated to boost the target segments further. As a result, a dominant share has been predicted for biopsy and liquid biopsy segments.
Research and Development Activities Becoming Key Focus of Companies
The rising burden of cancer is triggering innovation in diagnostic and treatment approaches. Both governments and critical companies are spending rigorously in research & development activities to advance cancer diagnostics and develop new and more effective cancer diagnostics tests.
Ongoing research in breast cancer diagnostics, including developing new biomarkers and genetic testing methods, is set to facilitate growth in Europe. Similarly, the introduction and popularity of targeted therapies & personalized diagnostics approaches will bode well for this business.
Companies are also exploring new imaging techniques, such as digital breast tomosynthesis (DBT), that detect smaller and earlier-stage tumors than conventional mammograms. This is expected to strengthen their regional presence and boost their revenue.
Industry Outlook
| Attributes | Key Insights |
|---|---|
| Base Value (2022) | US$ 3,949.1 million |
| Estimated Value (2023) | US$ 4,041.5 million |
| Projected Value (2033) | US$ 5,030.1 million |
| CAGR (2023 to 2033) | 2.2% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Breast and prostate cancer diagnostics represent a remarkable opportunity due to high precision, reduced invasiveness, and government policies. Effectively developing breast and prostate cancer diagnostics requires a comprehensive harnessing of expertise in diagnostic technologies.
In cancer diagnosis, groundbreaking technologies and innovations such as telehealth, artificial intelligence, CRISPR, cryo-electron microscopy, the Infinium Assay, and robotic surgery are instrumental in advancing and revolutionizing the diagnostic process. The rising popularity of these technologies is expected to boost revenue across Europe.
The growing prevalence of breast and prostate cancer across Europe triggers demand for cancer diagnostics. In recent years, there has been a spike in breast and prostate cancer cases in Europe. As per Globocan 2020, there were around 531086 new breast cancer cases and 473344 prostate cancer cases in Europe.
To counter the burden of cancer, early detection and treatment is necessary. As a result, people across Europe often opt for several cancer diagnostic procedures. This is expected to boost revenue in the region.
Europe breast and prostate cancer diagnostics revenue accounted for around 0.02% of Europe's cancer diagnostics sales (valued at US$ 16.7 billion) in 2022. In the forecast period, Europe's breast and prostate diagnostics revenue is set to increase at 2.2% CAGR, reaching US$ 5,030.1 million by 2033.
The increasing focus on population-based cancer screening and early detection programs in countries across Europe represents a significant opportunity for diagnostic companies specializing in cancer diagnostics and imaging technologies. These initiatives reflect a proactive approach to addressing the burden of cancer, as early detection is often a critical factor in improving patient outcomes and reducing healthcare costs associated with advanced-stage cancer treatment.
Imaging technologies are also crucial in cancer screening and early detection programs. Advanced imaging modalities, such as mammography, computed tomography (CT), magnetic resonance imaging (MRI), and ultrasound, are employed to visualize potential cancerous lesions, enabling clinicians to make timely and accurate diagnoses.
Europe's thriving landscape of clinical trials and research collaborations focused on cancer diagnostics and treatment has positioned the continent as a hub for innovation and advancement in the fight against cancer. Due to the above factors, Europe is expected to hold a prominent global revenue share.
Increasing breast and prostate cancer cases have become a serious concern across Europe. The disease not only results in loss of lives but also impacts the economic condition of countries. As a result, the government and other healthcare organizations are taking initiatives to counter this cancer burden, creating opportunities for companies.
Principal Consultant
Advancements in molecular diagnostics, particularly in Europe, are revolutionizing the landscape of cancer diagnosis and treatment. Europe has emerged as a leader in developing and applying cutting-edge molecular diagnostic technologies, such as next-generation sequencing (NGS) and liquid biopsy techniques.
The demand for NGS is expected to rise in Europe owing to its ability to identify specific genetic mutations, alterations, and variations in a patient's tumor DNA. These genetic insights would help provide critical information about the tumor's characteristics, such as its aggressiveness, susceptibility to targeted therapies, and potential resistance mechanisms.
Liquid biopsy techniques represent another remarkable advancement in molecular diagnostics. These non-invasive tests are projected to help analyze several biomarkers, such as circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and specific proteins in bodily fluids, including blood or urine.
Liquid biopsies are further anticipated to offer several advantages over traditional tissue biopsies, including minimal invasiveness and the ability to monitor disease progression over time. Another factor pushing their demand is the potential for early detection and treatment adjustment. The rising popularity of these cancer diagnostics tests will likely foster growth in Europe.
The growing research & technological advances are expected to create new opportunities for local and global manufacturers entering Europe. This is anticipated to boost Europe’s share in the worldwide breast and prostate cancer diagnostics business.
The high costs associated with diagnostic tests and imaging techniques for breast and prostate cancer present a significant barrier to access for several patients, particularly those in areas with limited healthcare resources. This financial burden is projected to affect individuals and strain healthcare systems, contributing to disparities in cancer care and outcomes.
One of the primary cost factors in cancer diagnostics is the price of medical equipment and technology. State-of-the-art imaging devices, such as MRI machines, CT scanners, and high-resolution ultrasound equipment, are expected to be essential for accurate cancer diagnosis and staging.
The advanced machines come with substantial price tags, making them less accessible in resource-constrained settings. Additionally, the maintenance and upgrading of such equipment require ongoing investments, further adding to the financial strain on healthcare facilities.
The need for timely and regular screenings further exacerbates the financial burden of cancer diagnostics. Early detection is crucial for improving cancer outcomes, but the need for frequent mammograms, prostate-to-specific antigen (PSA) tests, or other screening methods can strain household budgets. This is especially difficult for individuals without adequate health insurance coverage.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The below table shows the estimated growth rates of the top countries. Spain, France, and Germany are set to record higher CAGRs of 3.1%, 2.4%, and 2.1%, respectively, through 2033.
Growth Outlook by Key Countries
| Countries | Value-based CAGR |
|---|---|
| United Kingdom | 1.5% |
| Germany | 2.1% |
| Spain | 3.1% |
| Italy | 1.8% |
| France | 2.4% |
The United Kingdom is expected to remain a key country across Europe regarding breast and prostate cancer diagnostics. It is projected to attain a total valuation of US$ 667.7 million by 2033.
Demand for breast and prostate cancer diagnostics in the United Kingdom will likely rise at 1.5% CAGR during the assessment period. This is attributable to the rising prevalence of prostate cancer, favorable government support, and the growing popularity of tests such as biopsies.
Prostate cancer has risen to become the third-leading cause of cancer-related fatalities in the United Kingdom, surpassing breast cancer, despite notable improvements in survival rates for both diseases. This rise in prostate cancer cases prompts people to opt for several diagnostic tests nationwide.
According to the World Cancer Research Fund, over 150 cases of prostate cancer are diagnosed in the United Kingdom every day. This is expected to create a rising demand for prostate-specific antigen (PSA) screening and other tests. It is further anticipated to present new growth prospects for breast and prostate diagnostic companies in the country.
Prostate-specific antigen (PSA) screening has shown its potential to reduce prostate cancer mortality rates significantly. This blood test is anticipated to witness high demand as it allows for timely intervention by detecting prostate cancer at an early stage. The adoption of these tests is expected to boost revenue in the country.
Recognizing the importance of early detection and improved outcomes, the government is taking proactive steps to introduce new policies and initiatives related to PSA screening. These policies aim to increase awareness about the benefits of PSA testing, encourage routine screening for at-risk populations, and ensure that healthcare providers offer this screening as part of their preventive care services.
Germany is projected to dominate the Europe breast and prostate cancer diagnostics business by 2033. It is set to experience a CAGR of 2.1% during the forecast period. By 2033, total sales in Germany are expected to reach US$ 837.2 million.
The ongoing and progressive aging of Germany's population is anticipated to drive the demand for cancer screening. According to recent studies conducted in Germany, breast cancer was diagnosed at an older age in 2022 than in 2010.
Breast cancer is also considered the most prevalent cancer among women in Germany, making it a significant public health concern that substantially impacts individuals and the healthcare system. Hence, the growing prevalence of breast cancer in older women is expected to fuel demand in the country.
As per the Europe breast and prostate cancer diagnostics industry analysis, France is expected to witness a CAGR of 2.4% during the forecast period. It is anticipated to attain a valuation of US$ 561.5 million by 2033.
Several factors are expected to drive breast and prostate cancer diagnostics demand in France and facilitate growth. These include the increasing incidence of prostate cancer, rising awareness of early cancer detection, advances in cancer diagnostics technology, and favorable reimbursement policies.
Companies operating in France are actively investing in research & development activities to promote cancer diagnostics. This has paved the way for developing more accurate and sensitive tests, including liquid biopsies. The growing popularity of these advanced and non-invasive procedures is expected to boost revenue in France.
The government in France reimburses the cost of several cancer diagnostics tests. This is projected to make them more affordable to patients, driving their demand.
The below section predicts the biopsy segment to retain its dominance during the forecast period. It is projected to thrive at 1.7% CAGR through 2033. The imaging segment is anticipated to witness a steady CAGR of 2.8% in the forecast period.
Growth Outlook by Key Test
| Test | Value-based CAGR |
|---|---|
| Tumor Biomarkers Tests | 2.5% |
| Imaging | 2.8% |
| Biopsy | 1.7% |
| Liquid Biopsy | 2.4% |
| Immunohistochemistry | 1.4% |
| In Situ Hybridization | 2.1% |
By test, the biopsy segment held a 32.2% share in Europe in 2022. The demand for biopsies across the region is projected to rise at a CAGR of 1.7% during the assessment period. It is set to total a valuation of US$ 1,532.0 million by 2033.
Biopsy has become an ideal test for early diagnosis of cancer types, such as breast and prostate cancer. Its demand is anticipated to surge among patients as it is the only way to determine if a suspicious area is cancerous.
Biopsy is gaining traction due to additional information and the available post-to-research options. The information obtained from a biopsy is expected to help in staging cancer, which is essential for determining the extent of the disease and guiding treatment decisions.
Different types of biopsies would be used to diagnose breast and prostate cancer. For instance, women diagnosed with breast cancer often opt for a core needle biopsy. On the other hand, a transrectal ultrasound (TRUS)-guided biopsy has become a commonly opted type for prostate cancer.
High effectiveness and quick & reliable results are expected to fuel the demand for biopsies across Europe during the forecast period. The usage of imaging guidance, such as MRI or ultrasound, is also making biopsies attractive options for patients.
In the table below, the report has been analyzed based on indication. Out of the two indications, the breast cancer segment is anticipated to witness a CAGR of 1.9% in the assessment period. The prostate cancer segment, on the other hand, will likely exhibit a 2.5% from 2023 to 2033.
Growth Outlook by Key Indication
| Indication | Value-based CAGR |
|---|---|
| Breast Cancer | 1.9% |
| Prostate Cancer | 2.5% |
Based on indication, the breast cancer segment is anticipated to generate a revenue of US$ 2,552.6 million by 2033, holding a prominent share of 50.7%. This is attributable to the rising prevalence of breast cancer, growing cancer awareness, and increasing need for detecting breast cancer in its early stages to initiate proper treatment approaches.
Breast cancer has benefited significantly from early detection efforts, such as mammography screening and increased awareness. Routine screening is expected to allow for the identification of breast cancer at earlier, more treatable stages.
Robust research funding, breast cancer awareness campaigns, and advocacy efforts have all contributed to the improved prognosis by promoting early diagnosis, research breakthroughs, and improved treatment options. This, in turn, is expected to boost the target segment.
The report is analyzed in the table below based on the end user. Out of the five end users, the hospital-associated labs segment is anticipated to witness a CAGR of 2.0% in the assessment period. The independent diagnostic laboratories segment, on the other hand, will likely exhibit a 2.5% from 2023 to 2033.
Growth Outlook by Key End User
| End User | Value-based CAGR |
|---|---|
| Hospital-associated Labs | 2.0% |
| Independent Diagnostic Laboratories | 2.5% |
| Diagnostic Imaging Centers | 2.3% |
| Cancer Research Institutes | 3.0% |
| Others | 1.5% |
In Europe, hospital-associated labs hold a significant presence, representing a 44.6% share of the total value in 2022. The target segment is expected to thrive at a CAGR of 2.0% throughout the forecast period. This is attributable to the rising number of hospitals and patient inclination toward cancer diagnosis at hospitals.
Hospitals typically offer a wide range of diagnostic services under one roof, including advanced imaging technologies (MRI, CT scans, and PET scans), laboratory facilities for blood tests & biopsies, and access to specialists in several medical disciplines. This comprehensive approach is anticipated to ensure patients receive a thorough evaluation and diagnosis efficiently.
Organizations and manufacturers with robust procurement capabilities are well-positioned to foster growth and expand their businesses by collaborating with buyers & suppliers. They can innovate and create products that mutually enhance revenues and profits. Employing a holistic approach, they implement multiple strategies, including agreements, acquisitions, collaborations, and expansion, to drive progress and innovation in cancer diagnostics.
Recent Developments
| Attribute | Details |
|---|---|
| Estimated Value (2023) | US$ 4,041.5 million |
| Projected Value (2033) | US$ 5,030.1 million |
| Predicted CAGR (2023 to 2033) | 2.2% |
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2018 to 2022 |
| Industry Analysis | Value (US$ million) |
| Key Regions Covered | Western Europe; Eastern Europe; and the Rest of Europe |
| Key Countries Covered | Germany, France, Spain, Italy, BENELUX, Nordic Countries, United Kingdom, Poland, Hungary, Romania, Czech Republic |
| Key Segments Covered | Test, Indication, End User, and Region |
| Key Companies Profiled | Koninklijke Philips N.V.; F.Hoffmann to La Roche Ltd.; Abbott Laboratories, Inc.; Bio Rad Laboratories Inc.; General Electric (GE HealthCare); QIAGEN N.V.; Agilent Technologies, Inc.; Becton, Dickinson and Company; Cook Group Inc.; Danaher (Cepheid); Siemens Healthcare GmbH; Thermo Fisher Scientific Inc.; Illumina, Inc.; Hologic, Inc; Argon Medical Devices; Vortex Biosciences, Inc.; Canon Medical Systems Corporation; Merit Medical Systems |
| Report Coverage | Forecast, Competition Intelligence, Key Dynamics and Challenges, Strategic Growth Initiatives |
The total revenue in Europe is estimated to reach US$ 4,041.5 million in 2023.
Sales in Europe are projected to total US$ 5,030.1 million by 2033.
Demand in Europe is forecast to rise at 2.2% CAGR through 2033.
Sales across Europe grew at a CAGR of 1.6% between 2018 and 2022.
Continuous advancements in cancer diagnostics and rising cancer awareness are vital trends.
The top countries driving demand are the United Kingdom, Germany, France, Poland, and Italy.
Breast cancer is generally diagnosed through imaging tests and biopsies.
The United Kingdom held a revenue share of US$ 565.4 million in 2022.
In 2022, Poland had a value share of around 9.9% in Europe.
Germany is set to thrive at a CAGR of around 2.1% over the forecast period.
Koninklijke Philips N.V. and F.Hoffmann are the key players across Europe.
1. Executive Summary 1.1. Europe Industry Outlook 1.2. Demand Side Trends 1.3. Supply-Side Trends 1.4. Analysis and Recommendations 2. Demand Analysis Overview 2.1. Coverage / Taxonomy 2.2. Definition / Scope / Limitations 2.3. Inclusions and Exclusions 3. Key Trends 3.1. Key Trends Impacting Growth 3.2. Development/Innovation Trends 4. Value-Added Insights 4.1. Product Adoption Analysis 4.2. Disease Epidemiology 4.3. Reimbursement Landscape 4.4. Key Developments 4.5. Europe Regulatory Scenario 4.6. PESTEL Analysis 4.7. Porters Analysis 4.8. Supply Chain Analysis 4.9. Unmet needs and Opportunities 5. Background 5.1. Macro-Economic Factors 5.1.1. Europe Healthcare Expenditure 5.1.2. Life Science Spending Outlook 5.1.3. Overall Cancer Diagnostics Industry Outlook 5.2. Forecast Factors - Relevance and Impact 5.2.1. Cancer Incidence and Prevalence 5.2.2. Advancements in Diagnostic Technologies 5.2.3. Screening Programs 5.2.4. Genomic Data Sharing and Research Collaborations 5.2.5. Strategic Collaborations 5.2.6. Cancer Survivorship Programs 5.2.7. Biomarker Discovery and Validation 5.2.8. Health Technology Assessment (HTA) 5.2.9. Cancer Screening Controversies 5.3. Key Dynamics 5.3.1. Drivers 5.3.2. Restraints 5.3.3. Opportunity Analysis 6. Demand (in Value or Size in US$ million) Analysis 2018 to 2022 and Forecast, 2022 to 2033 6.1. Historical Sales Value (US$ million) Analysis, 2018 to 2022 6.2. Current and Future Value (US$ million) Projections, 2022 to 2033 6.2.1. Y-o-Y Growth Trend Analysis 6.2.2. Absolute $ Opportunity Analysis 7. Analysis 2018 to 2022 and Forecast 2022 to 2033, By Test 7.1. Introduction / Key Findings 7.2. Historical Size (US$ million) Analysis By Test, 2018 to 2022 7.3. Current and Future Size (US$ million) Analysis and Forecast By Test, 2022 to 2033 7.3.1. Tumor Biomarkers Tests 7.3.1.1. PSA Tests 7.3.1.2. CTC Tests 7.3.1.3. HER2 Tests 7.3.1.4. BRCA Tests 7.3.1.5. Others 7.3.2. Imaging 7.3.2.1. Ultrasound 7.3.2.2. Mammography 7.3.2.3. MRI Scan 7.3.2.4. PET Scan 7.3.2.5. CT Scan 7.3.2.6. SPECT and Others 7.3.3. Biopsy 7.3.3.1. Needle Biopsy 7.3.3.2. Endoscopic Biopsy 7.3.3.3. Bone Marrow Biopsy 7.3.3.4. Others 7.3.4. Liquid Biopsy 7.3.4.1. CTCs (Circulatory Tumor Cells) 7.3.4.2. ctNA (Circulating Tumor Nucleic Acid) 7.3.5. Immunohistochemistry 7.3.6. In Situ Hybridization 7.4. Attractiveness Analysis By Test 8. Analysis 2018 to 2022 and Forecast 2022 to 2033, By Indication 8.1. Introduction / Key Findings 8.2. Historical Size (US$ million) By Indication, 2018 to 2022 8.3. Current and Future Size (US$ million) Analysis and Forecast By Indication, 2022 to 2033 8.3.1. Breast Cancer 8.3.1.1. Invasive Ductal Carcinoma 8.3.1.2. Ductal Carcinoma in Situ 8.3.1.3. invasive Lobular Carcinoma 8.3.1.4. Triple Negative Breast Cancer 8.3.1.5. Others 8.3.2. Prostate Cancer 8.3.2.1. Adenocarcinoma 8.3.2.2. Squamous Cell Carcinoma 8.3.2.3. Transitional Cell Carcinoma 8.3.2.4. Neuroendocrine Tumors 8.3.2.5. Others 8.4. Attractiveness Analysis By Indication 9. Sales Analysis 2018 to 2022 and Forecast 2022 to 2033, By End User 9.1. Introduction / Key Findings 9.2. Historical Size (US$ million) By End User, 2018 to 2022 9.3. Current and Future Size (US$ million) Analysis and Forecast By End User, 2022 to 2033 9.3.1. Hospital Associated Labs 9.3.2. Independent Diagnostic Laboratories 9.3.3. Diagnostic Imaging Centers 9.3.4. Cancer Research Institutes 9.3.5. Others 9.4. Attractiveness Analysis By End User 10. Analysis 2018 to 2022 and Forecast 2022 to 2033, By Region 10.1. Introduction / Key Findings 10.2. Historical Size (US$ million) Trend Analysis by Region, 2018 to 2022 10.3. Current and Future Size (US$ million) Analysis and Forecast by Region, 2022 to 2033 10.3.1. Western Europe 10.3.1.1. United Kingdom 10.3.1.2. Germany 10.3.1.3. France 10.3.1.4. Italy 10.3.1.5. Spain 10.3.1.6. BENELUX 10.3.1.7. Nordics 10.3.2. Eastern Europe 10.3.2.1. Poland 10.3.2.2. Hungary 10.3.2.3. Romania 10.3.2.4. Russia 10.3.2.5. Czech Republic 10.3.3. Rest of Europe 10.4. Attractiveness Analysis by Region 11. United Kingdom Demand Analysis 2018 to 2022 and Forecast 2022 to 2033 11.1. Introduction 11.2. Historical Size (US$ million) Analysis by Taxonomy, 2018 to 2022 11.3. Current and Future Size (US$ million) Analysis and Forecast by Taxonomy, 2022 to 2033 11.3.1. By States 11.3.1.1. England 11.3.1.2. Wales 11.3.1.3. Northern Ireland 11.3.1.4. Scotland 11.3.2. By Test 11.3.3. By Indication 11.3.4. By End User 11.4. Attractiveness Analysis 11.4.1. By States 11.4.2. By Test 11.4.3. By Indication 11.4.4. By End User 11.5. State-Level Analysis and Forecast 11.5.1. England Demand Analysis 11.5.1.1. Introduction 11.5.1.2. Demand Analysis and Forecast by Taxonomy 11.5.1.2.1. Test 11.5.1.2.2. By Indication 11.5.1.2.3. By End User 11.5.2. Wales Demand Analysis 11.5.2.1. Introduction 11.5.2.2. Demand Analysis and Forecast by Taxonomy 11.5.2.2.1. Test 11.5.2.2.2. By Indication 11.5.2.2.3. By End User 11.5.3. Northern Ireland Demand Analysis 11.5.3.1. Introduction 11.5.3.2. Demand Analysis and Forecast by Taxonomy 11.5.3.2.1. Test 11.5.3.2.2. By Indication 11.5.3.2.3. By End User 11.5.4. Scotland Demand Analysis 11.5.4.1. Introduction 11.5.4.2. Demand Analysis and Forecast by Taxonomy 11.5.4.2.1. Test 11.5.4.2.2. By Indication 11.5.4.2.3. By End User 12. Germany Demand Analysis 2018 to 2022 and Forecast 2022 to 2033 12.1. Introduction 12.2. Historical Size (US$ million) Analysis by Taxonomy, 2018 to 2022 12.3. Current and Future Size (US$ million) Analysis and Forecast by Taxonomy, 2022 to 2033 12.3.1. By States 12.3.1.1. Baden-Württemberg 12.3.1.2. Bavaria 12.3.1.3. Lower Saxony 12.3.1.4. Hesse 12.3.1.5. Rest of Germany 12.3.2. By Test 12.3.3. By Indication 12.3.4. By End User 12.4. Attractiveness Analysis 12.4.1. By States 12.4.2. By Test 12.4.3. By Indication 12.4.4. By End User 12.5. States Level Analysis and Forecast 12.5.1. Baden-Württemberg Demand Analysis 12.5.1.1. Introduction 12.5.1.2. Demand Analysis and Forecast by Taxonomy 12.5.1.2.1. Test 12.5.1.2.2. By Indication 12.5.1.2.3. By End User 12.5.2. Bavaria Demand Analysis 12.5.2.1. Introduction 12.5.2.2. Demand Analysis and Forecast by Taxonomy 12.5.2.2.1. Test 12.5.2.2.2. By Indication 12.5.2.2.3. By End User 12.5.3. Argentina Demand Analysis 12.5.3.1. Introduction 12.5.3.2. Demand Analysis and Forecast by Taxonomy 12.5.3.2.1. Test 12.5.3.2.2. By Indication 12.5.3.2.3. By End User 12.5.4. Lower Saxony Demand Analysis 12.5.4.1. Introduction 12.5.4.2. Demand Analysis and Forecast by Taxonomy 12.5.4.2.1. Test 12.5.4.2.2. By Indication 12.5.4.2.3. By End User 12.5.5. Hesse Demand Analysis 12.5.5.1. Introduction 12.5.5.2. Demand Analysis and Forecast by Taxonomy 12.5.5.2.1. Test 12.5.5.2.2. By Indication 12.5.5.2.3. By End User 13. Spain Demand Analysis 2018 to 2022 and Forecast 2022 to 2033 13.1. Introduction 13.2. Historical Size (US$ million) Analysis by Taxonomy, 2018 to 2022 13.3. Current and Future Size (US$ million) Analysis and Forecast by Taxonomy, 2022 to 2033 13.3.1. By States 13.3.1.1. Madrid 13.3.1.2. Barcelona 13.3.1.3. Valencia 13.3.1.4. Seville 13.3.1.5. Rest of Spain 13.3.2. By Test 13.3.3. By Indication 13.3.4. By End User 13.4. Attractiveness Analysis 13.4.1. By States 13.4.2. By Test 13.4.3. By Indication 13.4.4. By End User 13.5. States Level Analysis and Forecast 13.5.1. Madrid Demand Analysis 13.5.1.1. Introduction 13.5.1.2. Demand Analysis and Forecast by Taxonomy 13.5.1.2.1. Test 13.5.1.2.2. By Indication 13.5.1.2.3. By End User 13.5.2. Barcelona Demand Analysis 13.5.2.1. Introduction 13.5.2.2. Demand Analysis and Forecast by Taxonomy 13.5.2.2.1. Test 13.5.2.2.2. By Indication 13.5.2.2.3. By End User 13.5.3. Valencia Demand Analysis 13.5.3.1. Introduction 13.5.3.2. Demand Analysis and Forecast by Taxonomy 13.5.3.2.1. Test 13.5.3.2.2. By Indication 13.5.3.2.3. By End User 13.5.4. Seville Demand Analysis 13.5.4.1. Introduction 13.5.4.2. Demand Analysis and Forecast by Taxonomy 13.5.4.2.1. Test 13.5.4.2.2. By Indication 13.5.4.2.3. By End User 14. Italy Demand Analysis 2018 to 2022 and Forecast 2022 to 2033 14.1. Introduction 14.2. Historical Size (US$ million) Analysis by Taxonomy, 2018 to 2022 14.3. Current and Future Size (US$ million) Analysis and Forecast by Taxonomy, 2022 to 2033 14.3.1. By States 14.3.1.1. Rome 14.3.1.2. Abruzzo 14.3.1.3. Basilicata 14.3.1.4. Calabria 14.3.1.5. Rest of Italy 14.3.2. By Test 14.3.3. By Indication 14.3.4. By End User 14.4. Attractiveness Analysis 14.4.1. By States 14.4.2. By Test 14.4.3. By Indication 14.4.4. By End User 14.5. States Level Analysis and Forecast 14.5.1. Rome Demand Analysis 14.5.1.1. Introduction 14.5.1.2. Demand Analysis and Forecast by Taxonomy 14.5.1.2.1. Test 14.5.1.2.2. By Indication 14.5.1.2.3. By End User 14.5.2. Abruzzo Demand Analysis 14.5.2.1. Introduction 14.5.2.2. Demand Analysis and Forecast by Taxonomy 14.5.2.2.1. Test 14.5.2.2.2. By Indication 14.5.2.2.3. By End User 14.5.3. Basilicata Demand Analysis 14.5.3.1. Introduction 14.5.3.2. Demand Analysis and Forecast by Taxonomy 14.5.3.2.1. Test 14.5.3.2.2. By Indication 14.5.3.2.3. By End User 14.5.4. Calabria Demand Analysis 14.5.4.1. Introduction 14.5.4.2. Demand Analysis and Forecast by Taxonomy 14.5.4.2.1. Test 14.5.4.2.2. By Indication 14.5.4.2.3. By End User 15. France Demand Analysis 2018 to 2022 and Forecast 2022 to 2033 15.1. Introduction 15.2. Historical Size (US$ million) Analysis by Taxonomy, 2018 to 2022 15.3. Current and Future Size (US$ million) Analysis and Forecast by Taxonomy, 2022 to 2033 15.3.1. By States 15.3.1.1. Auvergne - Rhône-Alpes 15.3.1.2. Bretagne (Brittany) 15.3.1.3. Bourgogne - Franche-Comté 15.3.1.4. Ile de France (Paris) 15.3.1.5. Rest of France 15.3.2. By Test 15.3.3. By Indication 15.3.4. By End User 15.4. Attractiveness Analysis 15.4.1. By States 15.4.2. By Test 15.4.3. By Indication 15.4.4. By End User 15.5. States Level Analysis and Forecast 15.5.1. Auvergne - Rhône-Alpes Demand Analysis 15.5.1.1. Introduction 15.5.1.2. Demand Analysis and Forecast by Taxonomy 15.5.1.2.1. Test 15.5.1.2.2. By Indication 15.5.1.2.3. By End User 15.5.2. Bretagne (Brittany) Demand Analysis 15.5.2.1. Introduction 15.5.2.2. Demand Analysis and Forecast by Taxonomy 15.5.2.2.1. Test 15.5.2.2.2. By Indication 15.5.2.2.3. By End User 15.5.3. Bourgogne - Franche-Comté Demand Analysis 15.5.3.1. Introduction 15.5.3.2. Demand Analysis and Forecast by Taxonomy 15.5.3.2.1. Test 15.5.3.2.2. By Indication 15.5.3.2.3. By End User 15.5.4. Ile de France (Paris) Demand Analysis 15.5.4.1. Introduction 15.5.4.2. Demand Analysis and Forecast by Taxonomy 15.5.4.2.1. Test 15.5.4.2.2. By Indication 15.5.4.2.3. By End User 16. BENELUX Demand Analysis 2018 to 2022 and Forecast 2022 to 2033 16.1. Introduction 16.2. Historical Size (US$ million) Analysis by Taxonomy, 2018 to 2022 16.3. Current and Future Size (US$ million) Analysis and Forecast by Taxonomy, 2022 to 2033 16.3.1. By Country 16.3.1.1. Belgium 16.3.1.2. Netherlands 16.3.1.3. Luxembourg 16.3.2. By Test 16.3.3. By Indication 16.3.4. By End User 16.4. Attractiveness Analysis 16.4.1. By Country 16.4.2. By Test 16.4.3. By Indication 16.4.4. By End User 16.5. Country Level Analysis and Forecast 16.5.1. Belgium Demand Analysis 16.5.1.1. Introduction 16.5.1.2. Demand Analysis and Forecast by Taxonomy 16.5.1.2.1. Test 16.5.1.2.2. By Indication 16.5.1.2.3. By End User 16.5.2. Netherland Demand Analysis 16.5.2.1. Introduction 16.5.2.2. Demand Analysis and Forecast by Taxonomy 16.5.2.2.1. Test 16.5.2.2.2. By Indication 16.5.2.2.3. By End User 16.5.3. Luxemburg Demand Analysis 16.5.3.1. Introduction 16.5.3.2. Demand Analysis and Forecast by Taxonomy 16.5.3.2.1. Test 16.5.3.2.2. By Indication 16.5.3.2.3. By End User 17. Nordics Demand Analysis 2018 to 2022 and Forecast 2022 to 2033 17.1. Introduction 17.2. Historical Size (US$ million) Analysis by Taxonomy, 2018 to 2022 17.3. Current and Future Size (US$ million) Analysis and Forecast by Taxonomy, 2022 to 2033 17.3.1. By Country 17.3.1.1. Denmark 17.3.1.2. Norway 17.3.1.3. Sweden 17.3.1.4. Finland 17.3.1.5. Rest of Nordics 17.3.2. By Test 17.3.3. By Indication 17.3.4. By End User 17.4. Attractiveness Analysis 17.4.1. By Country 17.4.2. By Test 17.4.3. By Indication 17.4.4. By End User 17.5. Country Level Analysis and Forecast 17.5.1. Denmark Demand Analysis 17.5.1.1. Introduction 17.5.1.2. Demand Analysis and Forecast by Taxonomy 17.5.1.2.1. Test 17.5.1.2.2. By Indication 17.5.1.2.3. By End User 17.5.2. Norway Demand Analysis 17.5.2.1. Introduction 17.5.2.2. Demand Analysis and Forecast by Taxonomy 17.5.2.2.1. Test 17.5.2.2.2. By Indication 17.5.2.2.3. By End User 17.5.3. Sweden Demand Analysis 17.5.3.1. Introduction 17.5.3.2. Demand Analysis and Forecast by Taxonomy 17.5.3.2.1. Test 17.5.3.2.2. By Indication 17.5.3.2.3. By End User 17.5.4. Finland Demand Analysis 17.5.4.1. Introduction 17.5.4.2. Demand Analysis and Forecast by Taxonomy 17.5.4.2.1. Test 17.5.4.2.2. By Indication 17.5.4.2.3. By End User 18. Poland Demand Analysis 2018 to 2022 and Forecast 2022 to 2033 18.1. Introduction 18.2. Historical Size (US$ million) Analysis by Taxonomy, 2018 to 2022 18.3. Current and Future Size (US$ million) Analysis and Forecast by Taxonomy, 2022 to 2033 18.3.1. By Test 18.3.2. By Indication 18.3.3. By End User 18.4. Attractiveness Analysis 18.4.1. By Test 18.4.2. By Indication 18.4.3. By End User 19. Hungary Demand Analysis 2018 to 2022 and Forecast 2022 to 2033 19.1. Introduction 19.2. Historical Size (US$ million) Analysis by Taxonomy, 2018 to 2022 19.3. Current and Future Size (US$ million) Analysis and Forecast by Taxonomy, 2022 to 2033 19.3.1. By Test 19.3.2. By Indication 19.3.3. By End User 19.4. Attractiveness Analysis 19.4.1. By Test 19.4.2. By Indication 19.4.3. By End User 20. Romania Demand Analysis 2018 to 2022 and Forecast 2022 to 2033 20.1. Introduction 20.2. Historical Size (US$ million) Analysis by Taxonomy, 2018 to 2022 20.3. Current and Future Size (US$ million) Analysis and Forecast by Taxonomy, 2022 to 2033 20.3.1. By Test 20.3.2. By Indication 20.3.3. By End User 20.4. Attractiveness Analysis 20.4.1. By Test 20.4.2. By Indication 20.4.3. By End User 21. Czech Republic Demand Analysis 2018 to 2022 and Forecast 2022 to 2033 21.1. Introduction 21.2. Historical Size (US$ million) Analysis by Taxonomy, 2018 to 2022 21.3. Current and Future Size (US$ million) Analysis and Forecast by Taxonomy, 2022 to 2033 21.3.1. By Test 21.3.2. By Indication 21.3.3. By End User 21.4. Attractiveness Analysis 21.4.1. By Test 21.4.2. By Indication 21.4.3. By End User 22. Russia Demand Analysis 2018 to 2022 and Forecast 2022 to 2033 22.1. Introduction 22.2. Historical Size (US$ million) Analysis by Taxonomy, 2018 to 2022 22.3. Current and Future Size (US$ million) Analysis and Forecast by Taxonomy, 2022 to 2033 22.3.1. By Test 22.3.2. By Indication 22.3.3. By End User 22.4. Attractiveness Analysis 22.4.1. By Test 22.4.2. By Indication 22.4.3. By End User 23. Rest of Demand Analysis 2018 to 2022 and Forecast 2022 to 2033 23.1. Introduction 23.2. Historical Size (US$ million) Analysis by Taxonomy, 2018 to 2022 23.3. Current and Future Size (US$ million) Analysis and Forecast by Taxonomy, 2022 to 2033 23.3.1. By Test 23.3.2. By Indication 23.3.3. By End User 23.4. Attractiveness Analysis 23.4.1. By Test 23.4.2. By Indication 23.4.3. By End User 24. Structure Analysis 24.1. Demand Analysis by Tier of Companies 24.2. Share Analysis of Top Players (%) 25. Competition Analysis 25.1. Competition Dashboard 25.2. Competition Benchmarking 25.3. Branding and Promotional Strategies 25.4. Key Development Analysis 25.5. Competition Deep Dive (Tentative List) 25.5.1. Koninklijke Philips N.V 25.5.1.1. Overview 25.5.1.2. Test Portfolio 25.5.1.3. Key Financials 25.5.1.4. SWOT Analysis 25.5.1.5. Key Developments 25.5.1.6. Sales Footprint 25.5.1.7. Strategy Overview 25.5.1.7.1. Strategy 25.5.1.7.2. Test Strategy 25.5.1.7.3. Channel Strategy 25.5.2. F.Hoffmann-La Roche Ltd. 25.5.2.1. Overview 25.5.2.2. Test Portfolio 25.5.2.3. Key Financials 25.5.2.4. SWOT Analysis 25.5.2.5. Key Developments 25.5.2.6. Sales Footprint 25.5.2.7. Strategy Overview 25.5.2.7.1. Strategy 25.5.2.7.2. Test Strategy 25.5.2.7.3. Channel Strategy 25.5.3. Abbott Laboratories, Inc. 25.5.3.1. Overview 25.5.3.2. Test Portfolio 25.5.3.3. Key Financials 25.5.3.4. SWOT Analysis 25.5.3.5. Key Developments 25.5.3.6. Sales Footprint 25.5.3.7. Strategy Overview 25.5.3.7.1. Strategy 25.5.3.7.2. Test Strategy 25.5.3.7.3. Channel Strategy 25.5.4. Bio Rad Laboratories Inc. 25.5.4.1. Overview 25.5.4.2. Test Portfolio 25.5.4.3. Key Financials 25.5.4.4. SWOT Analysis 25.5.4.5. Key Developments 25.5.4.6. Sales Footprint 25.5.4.7. Strategy Overview 25.5.4.7.1. Strategy 25.5.4.7.2. Test Strategy 25.5.4.7.3. Channel Strategy 25.5.5. General Electric (GE HealthCare) 25.5.5.1. Overview 25.5.5.2. Test Portfolio 25.5.5.3. Key Financials 25.5.5.4. SWOT Analysis 25.5.5.5. Key Developments 25.5.5.6. Sales Footprint 25.5.5.7. Strategy Overview 25.5.5.7.1. Strategy 25.5.5.7.2. Test Strategy 25.5.5.7.3. Channel Strategy 25.5.6. QIAGEN N.V. 25.5.6.1. Overview 25.5.6.2. Test Portfolio 25.5.6.3. Key Financials 25.5.6.4. SWOT Analysis 25.5.6.5. Key Developments 25.5.6.6. Sales Footprint 25.5.6.7. Strategy Overview 25.5.6.7.1. Strategy 25.5.6.7.2. Test Strategy 25.5.6.7.3. Channel Strategy 25.5.7. Agilent Technologies, Inc. 25.5.7.1. Overview 25.5.7.2. Test Portfolio 25.5.7.3. Key Financials 25.5.7.4. SWOT Analysis 25.5.7.5. Key Developments 25.5.7.6. Sales Footprint 25.5.7.7. Strategy Overview 25.5.7.7.1. Strategy 25.5.7.7.2. Test Strategy 25.5.7.7.3. Channel Strategy 25.5.8. Becton, Dickinson and Company 25.5.8.1. Overview 25.5.8.2. Test Portfolio 25.5.8.3. Key Financials 25.5.8.4. SWOT Analysis 25.5.8.5. Key Developments 25.5.8.6. Sales Footprint 25.5.8.7. Strategy Overview 25.5.8.7.1. Strategy 25.5.8.7.2. Test Strategy 25.5.8.7.3. Channel Strategy 25.5.9. Cook Group Inc. 25.5.9.1. Overview 25.5.9.2. Test Portfolio 25.5.9.3. Key Financials 25.5.9.4. SWOT Analysis 25.5.9.5. Key Developments 25.5.9.6. Sales Footprint 25.5.9.7. Strategy Overview 25.5.9.7.1. Strategy 25.5.9.7.2. Test Strategy 25.5.9.7.3. Channel Strategy 25.5.10. Danaher (Cepheid) 25.5.10.1. Overview 25.5.10.2. Test Portfolio 25.5.10.3. Key Financials 25.5.10.4. SWOT Analysis 25.5.10.5. Key Developments 25.5.10.6. Sales Footprint 25.5.10.7. Strategy Overview 25.5.10.7.1. Strategy 25.5.10.7.2. Test Strategy 25.5.10.7.3. Channel Strategy 25.5.11. Siemens Healthcare GmbH 25.5.11.1. Overview 25.5.11.2. Test Portfolio 25.5.11.3. Key Financials 25.5.11.4. SWOT Analysis 25.5.11.5. Key Developments 25.5.11.6. Sales Footprint 25.5.11.7. Strategy Overview 25.5.11.7.1. Strategy 25.5.11.7.2. Test Strategy 25.5.11.7.3. Channel Strategy 25.5.12. Thermo Fisher Scientific Inc. 25.5.12.1. Overview 25.5.12.2. Test Portfolio 25.5.12.3. Key Financials 25.5.12.4. SWOT Analysis 25.5.12.5. Key Developments 25.5.12.6. Sales Footprint 25.5.12.7. Strategy Overview 25.5.12.7.1. Strategy 25.5.12.7.2. Test Strategy 25.5.12.7.3. Channel Strategy 25.5.13. Illumina, Inc. 25.5.13.1. Overview 25.5.13.2. Test Portfolio 25.5.13.3. Key Financials 25.5.13.4. SWOT Analysis 25.5.13.5. Key Developments 25.5.13.6. Sales Footprint 25.5.13.7. Strategy Overview 25.5.13.7.1. Strategy 25.5.13.7.2. Test Strategy 25.5.13.7.3. Channel Strategy 25.5.14. Hologic, Inc 25.5.14.1. Overview 25.5.14.2. Test Portfolio 25.5.14.3. Key Financials 25.5.14.4. SWOT Analysis 25.5.14.5. Key Developments 25.5.14.6. Sales Footprint 25.5.14.7. Strategy Overview 25.5.14.7.1. Strategy 25.5.14.7.2. Test Strategy 25.5.14.7.3. Channel Strategy 25.5.15. Argon Medical Devices 25.5.15.1. Overview 25.5.15.2. Test Portfolio 25.5.15.3. Key Financials 25.5.15.4. SWOT Analysis 25.5.15.5. Key Developments 25.5.15.6. Sales Footprint 25.5.15.7. Strategy Overview 25.5.15.7.1. Strategy 25.5.15.7.2. Test Strategy 25.5.15.7.3. Channel Strategy 25.5.16. Vortex Biosciences, Inc. 25.5.16.1. Overview 25.5.16.2. Test Portfolio 25.5.16.3. Key Financials 25.5.16.4. SWOT Analysis 25.5.16.5. Key Developments 25.5.16.6. Sales Footprint 25.5.16.7. Strategy Overview 25.5.16.7.1. Strategy 25.5.16.7.2. Test Strategy 25.5.16.7.3. Channel Strategy 25.5.17. Canon Medical Systems Corporation 25.5.17.1. Overview 25.5.17.2. Test Portfolio 25.5.17.3. Key Financials 25.5.17.4. SWOT Analysis 25.5.17.5. Key Developments 25.5.17.6. Sales Footprint 25.5.17.7. Strategy Overview 25.5.17.7.1. Strategy 25.5.17.7.2. Test Strategy 25.5.17.7.3. Channel Strategy 25.5.18. Merit Medical Systems 25.5.18.1. Overview 25.5.18.2. Test Portfolio 25.5.18.3. Key Financials 25.5.18.4. SWOT Analysis 25.5.18.5. Key Developments 25.5.18.6. Sales Footprint 25.5.18.7. Strategy Overview 25.5.18.7.1. Strategy 25.5.18.7.2. Test Strategy 25.5.18.7.3. Channel Strategy 26. Assumptions and Acronyms Used 27. Research Methodology
Explore Healthcare Insights
View Reports
Breast and Prostate Cancer Diagnostics Industry Analysis in Europe
